Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604123 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults
A Phase 2 study of Allergic Rhinitis, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT00604123: Completed Phase 2 study of Allergic Rhinitis, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00604123 is a Phase 2 study of Allergic Rhinitis that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 74 participants, below the 102-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00604123, a Phase 2 study of Allergic Rhinitis, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the clinical effectiveness, safety and pharmacokinetics of JNJ-17166864 in patients with seasonal allergic rhinitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-17166864
Study Locations (1)
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00604123 record still lists
NCT00604123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 102-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00604123 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00604123 about?
NCT00604123 is a clinical study titled "A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults". The purpose of this study is to evaluate the clinical effectiveness, safety and pharmacokinetics of JNJ-17166864 in patients with seasonal allergic rhinitis.
What is the current status of trial NCT00604123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2008-01. Estimated completion is 2008-02.
What conditions does trial NCT00604123 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00604123?
The interventions under investigation include: Placebo (DRUG), JNJ-17166864 (DRUG).
Who is sponsoring clinical trial NCT00604123?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604123 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00604123's enrollment target sits among peer trials
74 10th of 23 higher than 13 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
COMPLETED · Phase 2
-
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
COMPLETED · Phase 2
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia